Generation of Neutralizing Antibodies and Divergence of SIVmac239 in Cynomolgus Macaques Following Short-Term Early Antiretroviral Therapy

English version České info

Neutralizing antibodies (NAb) able to react to heterologous viruses are generated during natural HIV-1 infection in some individuals. Further knowledge is required in order to understand the factors contributing to induction of cross-reactive NAb responses. Here a well-established model of experimental pathogenic infection in cynomolgus macaques, which reproduces long-lasting HIV-1 infection, was used to study the NAb response as well as the viral evolution of the highly neutralization-resistant SIVmac239. Twelve animals were infected intravenously with SIVmac239. Antiretroviral therapy (ART) was initiated ten days post-inoculation and administered daily for four months. Viral load, CD4⁺ T-cell counts, total IgG levels, and breadth as well as strength of NAb in plasma were compared simultaneously over 14 months. In addition, envs from plasma samples were sequenced at three time points in all animals in order to assess viral evolution. We report here that seven of the 12 animals controlled viremia to below 10⁴ copies/ml of plasma after discontinuation of ART and that this control was associated with a low level of evolutionary divergence. Macaques that controlled viral load developed broader NAb responses early on. Furthermore, escape mutations, such as V67M and R751G, were identified in virus sequenced from all animals with uncontrolled viremia. Bayesian estimation of ancestral population genetic diversity (PGD) showed an increase in this value in non-controlling or transient-controlling animals during the first 5.5 months of infection, in contrast to virus-controlling animals. Similarly, non- or transient controllers displayed more positively-selected amino-acid substitutions. An early increase in PGD, resulting in the generation of positively-selected amino-acid substitutions, greater divergence and relative high viral load after ART withdrawal, may have contributed to the generation of potent NAb in several animals after SIVmac239 infection. However, early broad NAb responses correlated with relatively preserved CD4⁺ T-cell numbers, low viral load and limited viral divergence.

Vyšlo v časopise: Generation of Neutralizing Antibodies and Divergence of SIVmac239 in Cynomolgus Macaques Following Short-Term Early Antiretroviral Therapy. PLoS Pathog 6(9): e32767. doi:10.1371/journal.ppat.1001084
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001084

Souhrn

Zdroje

1. AlbertJ

AbrahamssonB

NagyK

AureliusE

GainesH

1990 Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. Aids 4 107 112

2. MoogC

FleuryHJ

PellegrinI

KirnA

AubertinAM

1997 Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71 3734 3741

3. RichmanDD

WrinT

LittleSJ

PetropoulosCJ

2003 Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100 4144 4149

4. WeiX

DeckerJM

WangS

HuiH

KappesJC

2003 Antibody neutralization and escape by HIV-1. Nature 422 307 312

5. MooreJP

CaoY

LeuJ

QinL

KorberB

1996 Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 70 427 444

6. BunnikEM

PisasL

van NuenenAC

SchuitemakerH

2008 Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82 7932 7941

7. Doria-RoseNA

KleinRM

ManionMM

O'DellS

PhogatA

2009 Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83 188 199

8. SatherDN

ArmannJ

ChingLK

MavrantoniA

SellhornG

2009 Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 757 769

9. SimekMD

RidaW

PriddyFH

PungP

CarrowE

2009 Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83 7337 7348

10. ZhangYJ

FracassoC

FioreJR

BjorndalA

AngaranoG

1997 Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 176 1180 1187

11. CaoY

QinL

ZhangL

SafritJ

HoDD

1995 Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332 201 208

12. CeciliaD

KleebergerC

MunozA

GiorgiJV

Zolla-PaznerS

1999 A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179 1365 1374

13. JollyPE

WeissHL

2000 Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates. Virology 273 52 59

14. StamatatosL

MorrisL

BurtonDR

MascolaJR

2009 Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15 866 870

15. HessellAJ

RakaszEG

TehraniDM

HuberM

WeisgrauKL

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84 1302 1313

16. HessellAJ

PoignardP

HunterM

HangartnerL

TehraniDM

2009 Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15 951 954

17. NishimuraY

IgarashiT

HaigwoodN

SadjadpourR

PlishkaRJ

2002 Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76 2123 2130

18. ParrenPW

MarxPA

HessellAJ

LuckayA

HarouseJ

2001 Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75 8340 8347

19. BabaTW

LiskaV

Hofmann-LehmannR

VlasakJ

XuW

2000 Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6 200 206

20. MascolaJR

StieglerG

VanCottTC

KatingerH

CarpenterCB

2000 Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 207 210

21. MascolaJR

LewisMG

StieglerG

HarrisD

VanCottTC

1999 Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73 4009 4018

22. ShibataR

IgarashiT

HaigwoodN

Buckler-WhiteA

OgertR

1999 Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5 204 210

23. PutkonenP

ThorstenssonR

GhavamzadehL

AlbertJ

HildK

1991 Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352 436 438

24. SchererE

DouekD

McMichaelA

2008 25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines. Clin Exp Immunol 154 6 14

25. LacknerAA

VeazeyRS

2007 Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 58 461 476

26. CoffinJM

1995 HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 483 489

27. KraftZ

DerbyNR

McCaffreyRA

NiecR

BlayWM

2007 Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 81 6402 6411

28. CagigiA

NilssonA

De MilitoA

ChiodiF

2008 B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 26 3016 3025

29. YokoyamaS

1988 Molecular evolution of the Human and Simian immunideficienct viruses. Mol Biol Evol 5 645 649

30. ShankarappaR

MargolickJB

GangeSJ

RodrigoAG

UpchurchD

1999 Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73 10489 10502

31. PowerJP

DavidsonF

O'RiordanJ

SimmondsP

YapPL

1995 Hepatitis C infection from anti-D immunoglobulin. Lancet 346 372 373

32. OgataN

AlterHJ

MillerRH

PurcellRH

1991 Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 88 3392 3396

33. HarveyPH

PagelMD

1991 The Comparative Method in Evolutionary Biology Oxford Oxford University Press 239

34. SalemiM

VandammeAM

2003 The Phylogenetics Handbook-A practical approach to DNA and protein phylogeny Cambridge Cambridge University Press 406

35. LemeyP

Van DoorenS

VandammeAM

2005 Evolutionary dynamics of human retroviruses investigated through full-genome scanning. Mol Biol Evol 22 942 951

36. NowakMA

LloydAL

VasquezGM

WiltroutTA

WahlLM

1997 Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 71 7518 7525

37. OxeniusA

PriceDA

EasterbrookPJ

O'CallaghanCA

KelleherAD

2000 Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 97 3382 3387

38. KarlssonI

MalleretB

BrochardP

DelacheB

CalvoJ

2007 Dynamics of T-cell responses and memory T cells during primary simian immunodeficiency virus infection in cynomolgus macaques. J Virol 81 13456 13468

39. MattapallilJJ

DouekDC

HillB

NishimuraY

MartinM

2005 Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 1093 1097

40. SatoS

YusteE

LauerWA

ChangEH

MorganJS

2008 Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol 82 9739 9752

41. FultzPN

McClureHM

AndersonDC

SwensonRB

AnandR

1986 Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A 83 5286 5290

42. ZhangYJ

OhmanP

PutkonenP

AlbertJ

WaltherL

1993 Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. Virology 197 609 615

43. LaurenA

ThorstenssonR

FenyoEM

2006 Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. J Gen Virol 87 595 606

44. BenjaminiY

HochbergY

1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 57 289 300

45. RambautA

PosadaD

CrandallKA

HolmesEC

2004 The causes and consequences of HIV evolution. Nat Rev Genet 5 52 61

46. GaskillPJ

WatryDD

BurdoTH

FoxHS

2005 Development and characterization of positively selected brain-adapted SIV. Virol J 2 44

47. MoriK

RinglerDJ

KodamaT

DesrosiersRC

1992 Complex determinants of macrophage tropism in env of simian immunodeficiency virus. J Virol 66 2067 2075

48. WyattR

KwongPD

DesjardinsE

SweetRW

RobinsonJ

1998 The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 705 711

49. RongR

LiB

LynchRM

HaalandRE

MurphyMK

2009 Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5 1 17

50. KuntzenT

TimmJ

BericalA

Lewis-XimenezLL

JonesA

2007 Viral sequence evolution in acute hepatitis C virus infection. J Virol 81 11658 11668

51. ClementsJE

MontelaroRC

ZinkMC

AmedeeAM

MillerS

1995 Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 69 2737 2744

52. ColeKS

RowlesJL

JagerskiBA

Murphey-CorbM

UnangstT

1997 Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 71 5069 5079

53. BinleyJM

LybargerEA

CrooksET

SeamanMS

GrayE

2008 Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 11651 11668

54. BalzariniJ

NaesensL

SlachmuyldersJ

NiphuisH

RosenbergI

1991 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. Aids 5 21 28

55. CorriganGE

HanssonEO

MornerA

BerryN

KallanderCF

2006 Reverse transcriptase viral load correlates with RNA in SIV/SHIV-infected macaques. AIDS Res Hum Retroviruses 22 917 923

56. ReevesJD

HibbittsS

SimmonsG

McKnightA

Azevedo-PereiraJM

1999 Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73 7795 7804

57. MornerA

BjorndalA

AlbertJ

KewalramaniVN

LittmanDR

1999 Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73 2343 2349

58. ScarlattiG

LombardiV

PlebaniA

PrincipiN

VegniC

1991 Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. Aids 5 1173 1178

59. DongM

ZhangPF

GriederF

LeeJ

KrishnamurthyG

2003 Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol 77 3119 3130

60. ShiY

BrandinE

VincicE

JanssonM

BlaxhultA

2005 Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 86 3385 3396

61. ShiY

AlbertJ

FrancisG

HolmesH

FenyoEM

2002 A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res Hum Retroviruses 18 957 967

62. EdgarRC

2004 MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32 1792 1797

63. GuindonS

GascuelO

2003 A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52 696 704

64. PosadaD

CrandallKA

1998 MODELTEST: testing the model of DNA substitution. Bioinformatics 14 817 818

65. PosadaD

2003 Using MODELTEST and PAUP* to select a model of nucleotide substitution. Curr Protoc Bioinformatics Chapter 6 Unit 6 5

66. PosadaD

2006 ModelTest Server: a web-based tool for the statistical selection of models of nucleotide substitution online. Nucleic Acids Res 34 W700 703

67. PondSL

FrostSD

MuseSV

2005 HyPhy: hypothesis testing using phylogenies. Bioinformatics 21 676 679

68. ZwicklDJ

2006 Genetic algoritm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. Ph.D. dissertation. The University of Texas Austin

69. ShannonCE

1948 A matematical theory of communication. The Bell Syst Tech J 27 379 423

70. KingmanJFC

1982 The coalescent. Stochastic Processes and their Applications. Stoch Proc App 13 235 248

71. DrummondAJ

RambautA

2007 BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7 214

72. DrummondAJ

HoSY

PhillipsMJ

RambautA

2006 Relaxed phylogenetics and dating with confidence. PLoS Biol 4 0699 0710

73. ArnoldK

BordoliL

KoppJ

SchwedeT

2006 The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 195 201

74. EmsleyP

CowtanK

2004 Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 2126 2132

75. ZhangM

GaschenB

BlayW

FoleyB

HaigwoodN

2004 Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14 1229 1246